Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 3 STUDY TO EVALUATE THE EFFICACY, IMMUNOGENICITY, AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS

NCT05035212 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05035212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05035212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 3 STUDY TO EVALUATE THE EFFICACY, IMMUNOGENICITY, AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 31, 2021
Completion date
January 18, 2027
Enrollment
38,861 (actual)
Sites
263

Conditions

As the registry lists them; a condition with its own page is linked.

lower respiratory tract illness